内镜诊疗器械是指配合内镜使用的检查及微创手术器械和耗材。临床医生通过内镜获得人体腔道内的实时动态图 像诊断病症，利用合适的器械取得活体组织进行体外检测，而后根据检测结果选择专用的微创手术器械开展特定 的手术治疗，达到对人体腔道内疾病诊疗目的，能够在微创条件下实现组织取样、息肉切除、止血以及病变处 理，从而减少患者创伤并缩短康复时间。其主要应用于消化内科、呼吸科的临床诊断及治疗。 内镜诊疗器械行业目前现状分析 0 1 一次性耗材占比持续提高 内镜诊疗器械中一次性产品的使用率不断提升，成为行业发展的主要方向。一次性活检钳、止血夹等耗材在临床 应用中具有显著优势，能够有效降低交叉感染风险，并简化医院消毒与维护流程。这类耗材尤其适合高频操作的 内镜中心和基层医疗机构，提升了操作便捷性和安全性。企业在生产过程中对材料选择、加工工艺和质量控制要 求严格，以确保一次性耗材在性能和安全性上的稳定性。 材料技术水平不断提升 内镜诊疗器械的材料技术在近年来有显著发展，医用级聚合物、医用硅胶、镍钛合金及低摩擦涂层等材料广泛应 用于活检钳及止血夹等产品。材料改进不仅提高了柔韧性、耐腐蚀性和耐高温性，也增强了操作舒适度和精确 度。高性 ...

Core Insights - Company reported a revenue of 1.565 billion yuan for the first half of 2025, a year-on-year increase of 17.36%, and a net profit of 363 million yuan, up 17.04% from the previous year [1] - The proportion of overseas revenue has increased to 58% of total income, indicating a strong global market presence [1] Group 1: Market Growth and Trends - The endoscopic market is experiencing rapid growth due to advancements in endoscopic surgery and related technologies, leading to increased demand for endoscopic instruments and consumables [1] - The global digestive endoscopy market was valued at $9.2 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 5.3%, reaching $13.1 billion by 2028 [1] - The global endoscopic diagnostic and therapeutic device market is projected to reach $7 billion by 2025, with an overall growth rate of 6% [1] Group 2: Company Innovations and R&D - Company has a deep understanding of the development trends in minimally invasive technology and clinical needs, having developed nearly 30 core technologies across six major areas of endoscopic diagnosis and treatment [2] - R&D investment for the first half of 2025 was 88.28 million yuan, accounting for 5.64% of revenue, focusing on innovation-driven growth [2] - New innovative products, including the three-arm clamp, have received market approval, and several projects are in the registration submission phase [2] Group 3: Global Expansion and Sustainability - Company has emphasized global expansion, with overseas revenue and profits showing significant growth, up 45% year-on-year [3] - The acquisition of 51% of Spanish company Creo Medical S.L.U. in February marks a significant step in expanding into the European market, with integration progressing smoothly [3] - The construction and operational preparation of the manufacturing center in Thailand is on track to commence production by the end of the year, enhancing the global supply chain [3]